來凱醫藥(2105.HK)將在2024國際婦科腫瘤協會(IGCS)年會上公佈LAE002聯合信迪利單抗及化療在免疫治療耐藥人羣取得的重要進展
2024年8月7日——來凱醫藥(2105.HK)宣佈,公司將在2024年度國際婦科腫瘤協會(IGCS)全球年會上,公佈三藥聯合——LAE002 (afuresertib,一種口服AKT抑制劑)聯合信迪利單抗和化療、針對抗PD-1/PD-L1耐藥的特定實體瘤患者I期臨牀研究數據。
在該項臨牀研究(clinicaltrials.gov, NCT05383482)中,觀察到多線治療失敗(包括抗PD-1和/或化療)的晚期宮頸癌和子宮內膜癌患者仍可對該聯合方案產生積極應答。
"作為來凱的核心產品之一,LAE002(afuresertib)聯合療法針對HR+乳腺癌、宮頸癌/子宮內膜癌的兩項臨牀研究,先後入選2024年歐洲腫瘤內科學會(ESMO)和國際婦科腫瘤協會兩大重量級學術年會,凸顯了其在癌症治療領域的積極療效和良好耐受的安全性。"來凱醫藥首席財務官鄒國強先生強調,很高興LAE002聯合信迪利單抗(市場領先的PD-1品牌)取得了階段性成果。來凱秉承開放、積極的態度,願攜手行業楚翹,滿足患者的重大未竟需求。"
鄒國強介紹,在靶向ActRII受體產品組合開發方面,來凱也取得了實質性進展。LAE102是公司自主研發針對ActRIIA的抗體,於2024年6月,中國I期臨牀試驗完成了首例受試者給藥。"我們正積極與國際領先的生物製藥集團探討在靶向ActRII受體產品組合進行戰略合作,以加快LAE102的開發及商業化。"
摘要標題:Afuresertib聯合信迪利單抗+白蛋白結合型紫杉醇治療實體瘤患者(主要為宮頸癌和子宮內膜癌)的I/II 期劑量遞增和療效/安全性研究
作者:沈琳教授(北京大學腫瘤醫院),尹如鐵教授(四川大學華西第二醫院)等
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.